Manuela Grazina

Manuela Grazina

Auto-generated profile, based on publicly available information

Manuela Grazina

Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in Developmental Medicine & Child Neurology
Verified
Journal Article
Closed access
GOG Oliveira
G Oliveira
LDL Diogo
L Diogo
MGM Grazina
M Grazina
PGP Garcia
P Garcia
AAA Ataíde
A Ataíde
COCr Oliveira
Cr Oliveira
A minority of cases of autism has been associated with several different organic conditions, including bioenergetic metabolism deficiency. In a population-based study, we screened associated medical conditions in a group of 120 children with autism (current age range 11y 5mo to 14y 4mo, mean age 12y 11mo [SD 9.6mo], male:female ratio 2.9:1). Children were diagnosed using Diagnostic and Statistical Manual of Mental Disorders criteria, the Autism Diagnostic Interview--Revised, and the Childhood Autism Rating Scale; 76% were diagnosed with typical autism and 24% with atypical autism. Cognitive functional level was assessed with the Griffiths scale and the Wechsler Intelligence Scale for Children and was in the normal range in 17%. Epilepsy was present in 19 patients. Plasma lactate levels were measured in 69 patients, and in 14 we found hyperlactacidemia. Five of 11 patients studied were classified with definite mitochondrial respiratory chain disorder, suggesting that this might be one of the most common disorders associated with autism (5 of 69; 7.2%) and warranting further investigation.

6 December 2006 in Journal of Autism and Developmental Disorders
Verified
Journal Article
Closed access
PDF file
CCCatarina Correia
Catarina Correia
ACAna M. Coutinho
Ana M. Coutinho
LDLuísa Diogo
Luísa Diogo
MGManuela Grazina
Manuela Grazina
CMCarla Marques
Carla Marques
AVAstrid Moura Vicente
Astrid Moura Vicente

27 July 2012 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
DADaniela M. Arduíno
Daniela M. Arduíno
Raquel EstevesRaquel Esteves
Raquel Esteves
LCLuisa Cortes
Luisa Cortes
DSDiana F. Silva
Diana F. Silva
BPBindi Patel
Bindi Patel
SCSandra Morais Cardoso
Sandra Morais Cardoso
Abnormal presence of autophagic vacuoles is evident in brains of patients with Parkinson's disease (PD), in contrast to the rare detection of autophagosomes in a normal brain. However, the actual cause and pathological significance of these observations remain unknown. Here, we demonstrate a role for mitochondrial metabolism in the regulation of the autophagy-lysosomal pathway in ex vivo and in vitro models of PD. We show that transferring mitochondria from PD patients into cells previously depleted of mitochondrial DNA is sufficient to reproduce the alterations in the autophagic system observed in PD patient brains. Although the initial steps of this pathway are not compromised, there is an increased accumulation of autophagosomes associated with a defective autophagic activity. We prove that this functional decline was originated from a deficient mobilization of autophagosomes from their site of formation toward lysosomes due to disruption in microtubule-dependent trafficking. This contributed directly to a decreased proteolytic flux of α-synuclein and other autophagic substrates. Our results lend strong support for a direct impact of mitochondria in autophagy as defective autophagic clearance ability secondary to impaired microtubule trafficking is driven by dysfunctional mitochondria. We uncover mitochondria and mitochondria-dependent intracellular traffic as main players in the regulation of autophagy in PD.

1 September 2016 in Mitochondrion
Verified
Journal Article
Closed access
DYDèlia Yubero
Dèlia Yubero
RMRaquel Montero
Raquel Montero
Miguel A. MartinMiguel A. Martin
Miguel A. Martin
JMJulio Montoya
Julio Montoya
ARAntonia Ribes
Antonia Ribes
GCGloria Teresa Brea Calvo
Gloria Teresa Brea Calvo

4 November 2014 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
MAMaria Apellaniz-Ruiz
Maria Apellaniz-Ruiz
LIL Inglada-Pérez
L Inglada-Pérez
MNM E G Naranjo
M E G Naranjo
LSL Sánchez
L Sánchez
VMV Mancikova
V Mancikova
Cristina Rodriguez-AntonaCristina Rodriguez-Antona
Cristina Rodriguez-Antona

2 August 2019 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
Fernanda Rodrigues-SoaresFernanda Rodrigues-Soares
Fernanda Rodrigues-Soares
EPEva M. Peñas‐Lledó
Eva M. Peñas‐Lledó
ETEduardo Tarazona‐Santos
Eduardo Tarazona‐Santos
MSMartha Sosa‐Macías
Martha Sosa‐Macías
Enrique TeranEnrique Teran
Enrique Teran
RPRibef Ibero‐American Network Of Pharmacogenetics And Pharmacogenomics
Ribef Ibero‐American Network Of Pharmacogenetics And Pharmacogenomics